The use of a probiotic strain of Lactobacillus rhamnosus and an oligosaccharide mixture which comprises 5-70 wt % of at least one N-acetylated oligosaccharide selected from the group comprising GalNAc.alpha.1,3Gal.beta.1,4Glc and Gal.beta.1,6GalNAc.alpha.1,3Gal.beta.1,4Glc, 20-90 wt % of at least one neutral oligosaccharide selected from the group comprising Gal.beta.1,6Gal, Gal.beta.1,6Gal.beta.1,4Glc Gal.beta.1,6Gal.beta.1,6Glc, Gal.beta.1,3Gal.beta.1,3Glc, Gal.beta. 1,3Gal.beta. 1,4GIc, Gal.beta. 1,6Gal.beta. 1,6Gal.beta. 1,4GIc, Gal.beta. 1,6Gal.beta. 1,3Gal.beta. 1,4GIc Gal.beta.1,3Gal.beta.1,6Gal.beta.1,4Glc and Gal.beta.1,3Gal.beta.1,3Gal.beta.1, 4GIc and 5-50 wt % of at least one sialylated oligosaccharide selected from the group comprising NeuAc.alpha.2,3Gal.beta.1,4GIc and NeuAc.alpha.2,6Gal.beta.1,4Glc in the manufacture of a medicament or therapeutic nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants delivered by caesarean section is disclosed.